NASDAQ: ABSIAbsci Corp Stock
$1.88+0.04 (+2.17%)
Updated Jun 2, 2023
ABSI Price
$1.88
Fair Value Price
N/A
Market Cap
$173.91M
52 Week Low
$1.13
52 Week High
$7.04
P/E
-1.72x
P/B
0.68x
P/S
25.83x
PEG
N/A
Dividend Yield
N/A
Revenue
$6.20M
Earnings
-$98.77M
Gross Margin
100%
Operating Margin
-1,593.38%
Profit Margin
-1,593.8%
Debt to Equity
0.17
Operating Cash Flow
-$80M
Beta
2
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ABSI Overview
Absci Corp. partners offers its Integrated Drug Creation platform that uses synthetic biology technologies and deep learning artificial intelligence to identify novel drug targets, discover biotherapeutic candidates, and generate the cell lines to manufacture them, all in a single process. Absci Corp was founded in 2011 and is headquartered in Vancouver, WA.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ABSI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ABSI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ABSI is good value based on its book value relative to its share price (0.68x), compared to the US Biotechnology industry average (5.19x)
P/B vs Industry Valuation
ABSI is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ABSI due diligence checks available for Premium users.
Be the first to know about important ABSI news, forecast changes, insider trades & much more!
ABSI News
Valuation
ABSI fair value
Fair Value of ABSI stock based on Discounted Cash Flow (DCF)
Price
$1.88
Fair Value
$3.24
Undervalued by
41.94%
ABSI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ABSI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.72x
Industry
11.51x
Market
52.74x
ABSI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.68x
Industry
5.19x
ABSI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ABSI's financial health
Profit margin
Revenue
$1.3M
Net Income
-$23.4M
Profit Margin
-1,840.4%
ABSI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ABSI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$295.8M
Liabilities
$41.8M
Debt to equity
0.17
ABSI's short-term assets ($165.32M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ABSI's short-term assets ($165.32M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ABSI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$20.1M
Investing
-$27.3M
Financing
-$1.1M
ABSI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ABSI vs Biotech Stocks
Absci Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.